Last reviewed · How we verify
Refresh Tears 0.5% Lubricant Eye Drops
Refresh Tears provides ocular lubrication by supplementing natural tear film to relieve dry eye symptoms.
Refresh Tears provides ocular lubrication by supplementing natural tear film to relieve dry eye symptoms. Used for Dry eye disease / Keratoconjunctivitis sicca, Ocular irritation and discomfort.
At a glance
| Generic name | Refresh Tears 0.5% Lubricant Eye Drops |
|---|---|
| Also known as | Carboxy-methylcellulose sodium lubricant eye drops 0.5%w/v |
| Sponsor | Minnesota Eye Consultants, P.A. |
| Drug class | Artificial tear / Lubricant eye drop |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This product contains carboxymethylcellulose sodium 0.5%, a lubricating agent that mimics the viscous component of natural tears. It forms a protective film over the cornea and conjunctiva, reducing friction and evaporation while providing sustained moisture to the ocular surface. This mechanical lubrication alleviates discomfort associated with dry eye disease.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
- Ocular irritation and discomfort
Common side effects
- Transient blurred vision
- Eye irritation
- Ocular discomfort
Key clinical trials
- Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome (PHASE4)
- CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops (PHASE2)
- The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer (PHASE4)
- Bevacizumab Injection for Recurrent Pterygium
- Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: